{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:14:43Z","timestamp":1763662483260},"reference-count":24,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alemtuzumab is a monoclonal antibody to CD52 that has activity in T-cell leukemia and lymphoma. This study aims to describe the complications and outcomes of a subset of patients with mycosis fungoides\/Se\u0301zary syndrome who were treated with alemtuzumab. Four of 8 patients, with no prior history of cardiac problems, developed significant cardiac toxicity (congestive heart failure or arrhythmia) that mostly improved after alemtuzumab discontinuation. The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation.<\/jats:p>","DOI":"10.1182\/blood-2003-07-2345","type":"journal-article","created":{"date-parts":[[2004,4,13]],"date-time":"2004-04-13T00:13:50Z","timestamp":1081815230000},"page":"655-658","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":106,"title":["Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Se\u0301zary syndrome"],"prefix":"10.1182","volume":"104","author":[{"given":"Daniel J.","family":"Lenihan","sequence":"first","affiliation":[{"name":"From the Departments of Cardiology, Dermatology, Leukemia, and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro J.","family":"Alencar","sequence":"additional","affiliation":[{"name":"From the Departments of Cardiology, Dermatology, Leukemia, and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Yang","sequence":"additional","affiliation":[{"name":"From the Departments of Cardiology, Dermatology, Leukemia, and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"From the Departments of Cardiology, Dermatology, Leukemia, and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"From the Departments of Cardiology, Dermatology, Leukemia, and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"From the Departments of Cardiology, Dermatology, Leukemia, and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021217533812500_REF1","doi-asserted-by":"crossref","unstructured":"Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol. 2003;21: 1874-1881.","DOI":"10.1200\/JCO.2003.09.113"},{"key":"2020021217533812500_REF2","doi-asserted-by":"crossref","unstructured":"Lundin A, O\u0308sterborg A, Brittinger G, et al. Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol. 1998;16: 3257-3263.","DOI":"10.1200\/JCO.1998.16.10.3257"},{"key":"2020021217533812500_REF3","doi-asserted-by":"crossref","unstructured":"Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98; 773-778.","DOI":"10.1002\/cncr.11551"},{"key":"2020021217533812500_REF4","doi-asserted-by":"crossref","unstructured":"Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002; 19(suppl): S27-S32.","DOI":"10.1385\/MO:19:2S:S27"},{"key":"2020021217533812500_REF5","doi-asserted-by":"crossref","unstructured":"Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol2003;71: 250-256.","DOI":"10.1034\/j.1600-0609.2003.00143.x"},{"key":"2020021217533812500_REF6","doi-asserted-by":"crossref","unstructured":"Pangalis GA, Dimopoulou MN, Angelopoulou MK, et al. Campath-1H (Anti-CD52) monoclonal antibody therapy in lymproliferative disorders. Med Oncol. 2001;18:2: 99-107.","DOI":"10.1385\/MO:18:2:99"},{"key":"2020021217533812500_REF7","doi-asserted-by":"crossref","unstructured":"Keating MJ, Cazin B, Coutre\u0301 S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20: 205-213.","DOI":"10.1200\/JCO.20.1.205"},{"key":"2020021217533812500_","doi-asserted-by":"crossref","unstructured":"Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath 1-H) in patients who failed fludarabine: results of a large international study. Blood. 2002;99: 3554-3561.","DOI":"10.1182\/blood.V99.10.3554"},{"key":"2020021217533812500_REF9","doi-asserted-by":"crossref","unstructured":"Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I\/II study. Ann Hematol. 2002;81: 26-32.","DOI":"10.1007\/s00277-001-0394-7"},{"key":"2020021217533812500_REF10","doi-asserted-by":"crossref","unstructured":"Lundin J, Hagberg H, Repp R, et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) in patients with advanced mycosis fungoides\/Se\u0301zary syndrome. Blood. 2003;101: 4267-4272.","DOI":"10.1182\/blood-2002-09-2802"},{"key":"2020021217533812500_REF11","doi-asserted-by":"crossref","unstructured":"Damaj G, Rubio MT, Audard V, Hermine O. Severe cardiac toxicity after monoclonal antibody therapy [letter]. Eur J Haematol. 2002;68: 324.","DOI":"10.1034\/j.1600-0609.2002.00712.x"},{"key":"2020021217533812500_REF12","doi-asserted-by":"crossref","unstructured":"Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98: 1721-1726.","DOI":"10.1182\/blood.V98.6.1721"},{"key":"2020021217533812500_REF13","doi-asserted-by":"crossref","unstructured":"Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15: 2667-2672.","DOI":"10.1200\/JCO.1997.15.7.2667"},{"key":"2020021217533812500_REF14","doi-asserted-by":"crossref","unstructured":"Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH-1H: involvement of CD16 (Fc\u03b3RIII) and CD11a\/CD18 (LFA-1) on NK cells. J Clin Invest. 1996;98: 2819-2826.","DOI":"10.1172\/JCI119110"},{"key":"2020021217533812500_REF15","doi-asserted-by":"crossref","unstructured":"Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46: 296-304.","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#"},{"key":"2020021217533812500_REF16","doi-asserted-by":"crossref","unstructured":"Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119: 225-237.","DOI":"10.1093\/brain\/119.1.225"},{"key":"2020021217533812500_REF17","unstructured":"Pruzanski W, Urowitz MB, Grouix B, Vadas P. Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis. J Rheumatol. 1995;22: 1816-1819."},{"key":"2020021217533812500_REF18","unstructured":"Baker, AJ. Cellular and extracellular mechanisms causing myocardial stunning. J Am Coll Cardiol. 1999;34: 603-605."},{"key":"2020021217533812500_REF19","doi-asserted-by":"crossref","unstructured":"Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004;22: 322-329.","DOI":"10.1200\/JCO.2004.01.120"},{"key":"2020021217533812500_REF20","doi-asserted-by":"crossref","unstructured":"Ottaviani G, Matturi L, Rossi L, Jones D. Sudden death due to lymphomatous infiltration of the cardiac conduction system. Cardiovasc Pathol. 2003;12: 77-81.","DOI":"10.1016\/S1054-8807(02)00168-0"},{"key":"2020021217533812500_REF21","unstructured":"Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P. Troubles du rythme et de la conduction re\u0301ve\u0301lateurs d'une localisation cardiaque de lymphome malin non hodgkinien: A\u0300 propos de 2 cas. Arch Mal Coeur Vaiss. 2000;93: 1333-1338."},{"key":"2020021217533812500_","doi-asserted-by":"crossref","unstructured":"Servitje O, Limon A, Blanco A, et al. Cardiac involvement and molecular staging in a fatal case of mycosis fungoides. Br J Dermatol. 1999;141: 531-535.","DOI":"10.1046\/j.1365-2133.1999.03053.x"},{"key":"2020021217533812500_REF23","doi-asserted-by":"crossref","unstructured":"Roberts WC, Glancy DL, DeVita VT Jr. Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides). A study of 196 autopsy cases. Am J Cardiol. 1968;22: 85-107.","DOI":"10.1016\/0002-9149(68)90250-6"},{"key":"2020021217533812500_REF24","doi-asserted-by":"crossref","unstructured":"Rappaport H, Thomas LB. Mycosis fungoides: the pathology of extracutaneous involvement. Cancer. 1974;34: 1198-1229.","DOI":"10.1002\/1097-0142(197410)34:4<1198::AID-CNCR2820340431>3.0.CO;2-E"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/3\/655\/1700360\/zh801504000655.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/3\/655\/1700360\/zh801504000655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T23:36:46Z","timestamp":1585697806000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/3\/655\/18485\/Cardiac-toxicity-of-alemtuzumab-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-07-2345","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,1]]}}}